[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639969":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":10,"locations":20,"responsibleParty":40,"collaborators":42,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Centro Cardiologico Monzino","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Prospective Cohort",null,"Participants with paroxysmal or persistent atrial fibrillation undergoing clinically indicated transthoracic echocardiography (TTE) prior to catheter ablation with acquisition of a three-dimensional (3D) tricuspid valve dataset. Participants will undergo repeat transthoracic echocardiography at 12-month follow-up and rhythm monitoring with Holter ECG according to standard clinical practice. No study-specific interventions are planned.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control group","The study cohort will be compared with control populations undergoing clinically indicated transthoracic echocardiography:\n\n1. subjects with structurally normal hearts and no history of atrial fibrillation;\n2. patients with atrial fibrillation and ≥ moderate atrial functional tricuspid regurgitation, in the absence of significant left-sided valvular disease or prior valvular surgery.",[16],{"name":17,"affiliation":18,"role":19},"Gianluca Pontone, MD","Centro Cardiologico Monzino, IRCCS","PRINCIPAL_INVESTIGATOR",[21],{"facility":22,"status":23,"city":24,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Centro Cardiologico Monzino; IRCCS","RECRUITING","Milan","20133","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],9.18951,45.46427,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Chiara Centenaro","CONTACT","0258002031","chiara.centenaro@cardiologicomonzino.it",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[43],{"name":44,"class":6},"Istituto Clinico Humanitas","100639969","natural-history-of-atrial-fibrillation-induced-tricuspid-valve-remodeling-in-the-absence-of-significant-tricuspid-regurgitation-a-three-dimensional-echocardiographic-study-100639969",false,"NCT07617974","Natural History of Atrial Fibrillation-Induced Tricuspid Valve Remodeling in the Absence of Significant Tricuspid Regurgitation: A Three-Dimensional Echocardiographic Study","Natural History of Atrial Fibrillation-Induced Tricuspid Valve Remodeling in the Absence of Significant Tricuspid Regurgitation: A Three-Dimensional Echocardiographic Study (TRICUSPID-AF)","TRICUSPID-AF","Inclusion Criteria:\n\n* Consecutive patients with atrial fibrillation (paroxysmal or persistent) undergoing transthoracic echocardiography (TTE) prior to AF ablation with acquisition of a 3D TV dataset.\n\nEligible for enrollment in the control group will be:\n\n1. all consecutive patients with structurally normal hearts and no history of AF or;\n2. moderate atrial functional tricuspid regurgitation and AF, in the absence of significant left-sided valvular disease or prior valvular surgery.\n\nExclusion Criteria:\n\n* Moderate or greater TR assessed using a multiparametric approach;\n* Arrhythmias other than AF;\n* Prior AF ablations;\n* Rapid ventricular response (average HR \\>110 bpm) during baseline TTE;\n* Inadequate image quality",true,"ALL","18 Years",{"count":57,"type":58},66,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational, multicenter study aimed at characterizing tricuspid valve remodeling in patients with atrial fibrillation (AF) without significant tricuspid regurgitation (TR), in relation to AF burden progression.",[62,63],"Atrial Fibrillation (AF)","Tricuspid Regurgitation (TR)","2026-05-26",{"date":66,"type":67},"2026-06-01","ACTUAL",{"date":69,"type":67},"2026-05-04",{"date":71,"type":58},"2027-05-31",{"name":5,"class":6},1]